Press Releases
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Mar 28, 2023
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
Mar 17, 2023
Tiziana Life Sciences Highlighted in Forbes Article
Mar 17, 2023
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
Mar 08, 2023
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
Jan 04, 2023
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
Jan 03, 2023
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
Dec 29, 2022
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
Dec 27, 2022
Tiziana to Participate in January Investor Meetings
Dec 16, 2022
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
Dec 15, 2022
Displaying 41 - 50 of 467